PubMed Health⌕ Search

Biomedical subjects

P Andonov

Publications and source records attributed to P Andonov.

17 recordsLinked to original sources
PubMed2000

Prevention of herpes genitalis by the 'Bulgarian' vaccine F.HSV-2V(PRK): preliminary clinical evidence.

AIM: To examine the antigenic properties of the formalin-inactivated herpes simplex virus type 2 (HSV-2) virus-particle vaccine F. HSV-2V(PRK), which has been used therapeutically in Bulgaria for 30 years, and to make preliminary assessment of its potential protective efficacy by a follow-up of vaccinated patients with herpes genitalis. METHODS: Properties of the vaccine were examined by standard immunological laboratory tests. Fifty-five patients at risk of herpes genitalis received 2-4 vaccinations and were monitored during a 6-year follow-up. RESULTS: The vaccine was antigenic in laboratory tests and absorbed neutralizing antibody from hyperimmune rabbit serum against herpes simplex virus type 1 (HSV-1). In vaccinated patients, there was an overall contraction rate of herpes genitalis of 5.4%. There was no evidence of significant local or generalized adverse effects from vaccination. CONCLUSION: Bulgarian vaccine F.HSV-2V(PRK) may have protective efficacy, which, in association with its apparent safety from our findings and from its clinical use for over 30 years in Bulgaria, suggests that it should be scrutinized by a formal clinical trial.

Adolescent↗
PubMed1994

Seventeen years of application of herpes vaccines in Bulgaria.

This study reports on our experience with whole herpes simplex vaccines in Bulgaria for a period of 17 years. More than 1,500 immunized patients with herpes ophtalmicus showed a reduction of the recovery period, reduced number of the recurrences and reduced risk of visual damage. More than 14,000 patients suffering from other forms of herpes diseases for a longer period showed reduced recovery period and recurrence frequency in over 95% of the cases. Whole vaccines were well tolerable with no side effects. This report emphasizes the usefulness of whole herpes vaccines.

Adolescent↗
PubMed1986

Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.

DNA free antiherpes subunit vaccines were prepared from diploid human embryonic lung cells infected either with type 1 or type 2 herpes simplex viruses (HSV). Virion and membrane-bound virus-specific glycoproteins were solubilized with Nonidet P-40 and separated by ultracentrifugation. The antigenic properties of the vaccine were tested in guinea pigs. Antibody response was followed by virus neutralization and complement fixation. The vaccine itself was low-immunogenic, however its immunogenicity has considerably increased by usage of suitable adjuvants. In virus neutralization test higher antibody titre was found against homologous virus. The antibody response was related to protein content and to the frequency of vaccination.

Adjuvants, Immunologic↗
PubMed1980

Characterization of herpes simplex virus strains isolated from patients with various diseases.

Herpes simplex virus strains (HSV) were isolated from various herpetic diseases. These HSV-strains isolated in Bulgaria (687) and in other countries (13) were studied by the neutralization test using standard type specific rabbit antisera and human gamma globulin. The serotype distribution of all strains showed: HSV-1 = 323 strains, HSV-2 = 372 strains, 5 strains behaved antigenically intermediate. A close correlation between the serotype of the strains and the localization of the lesions was established. All but four strains (1.24 per cent) isolated from the head belong to HSV-1, and only six HSV-strains (1.9 per cent) from lesions with other localizations were not HSV-2. Within six months to 8 years 2 to 4 herpes strains were isolated repeatedly from 30 patients. In 23 of these cases they were identical and in the other they showed different biological (3) or antigenical (4) properties. The results suggest, that under natural conditions some HSV-intermediate strains may exist.

Antigens, Viral↗
PubMed1976

[Study of foot-and-mouth disease virus inhibitors in cell cultures and experimental animals].

Studied was the inhibiting action of some synthetic agents conditionally denoted No. 3 (benzamidazol), No. 76, and No. 78 (imidazolins) on the reproduction of the foot-and-mouth disease virus in cell cultures, newborn mice and guinea pigs. It was irrefutably demonstrated that all three agents produce an inhibiting effect on the virus. This effect was enhanced by the combined use of these inhibitors. It was found that best effect on the virus' replication produced the combination of agent No. 3 and some of the other two inhibitors. Discussed is the mechanism of action of these compounds.

Adsorption↗
PubMedDate not supplied

[Design of inactivated polyvalent antiherpes vaccines].

The variants of inactivated vaccine against herpes simplex virus have been developed: 1, 2 and 1 + 2. The first two variants consist of 5 different strains of herpes virus of the appropriate type, and the third variant of their mixture. The strains differ in their antigenic and biological characteristics. Complete inactivation of the virus suspension was achieved by treatment of the vaccine with formalin. Herpes vaccines were used for immunization of 477 patients with frequently relapsing forms of herpes of different localizations. The therapeutic-prophylactic effect of these vaccines indicates their relatively high efficacy: by the end of 9 months favourable results exceeded 95%. Better results were obtained with HSV-1 vaccine. A second cycle of immunization given to some patients resulted in markedly positive effect.

Animals↗